Risk of severe outcomes from COVID-19 in comorbid populations in the Omicron era: A systematic review and meta-analysis

IF 4.8 2区医学 Q1 INFECTIOUS DISEASES

International Journal of Infectious Diseases Pub Date : 2025-06-24 DOI:10.1016/j.ijid.2025.107958

Akvile Chapman , Dan H. Barouch , Gregory Y.H. Lip , Triantafyllos Pliakas , Eva Polverino , Harald Sourij , Sultan Abduljawad

{"title":"Risk of severe outcomes from COVID-19 in comorbid populations in the Omicron era: A systematic review and meta-analysis","authors":"Akvile Chapman , Dan H. Barouch , Gregory Y.H. Lip , Triantafyllos Pliakas , Eva Polverino , Harald Sourij , Sultan Abduljawad","doi":"10.1016/j.ijid.2025.107958","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>This is the first meta-analysis assessing mortality and hospitalization risk from COVID-19 in individuals with comorbidities versus those without during the Omicron era.</div></div><div><h3>Methods</h3><div>A systematic search (Embase, MEDLINE, PubMed, Europe PMC, Latin American and Caribbean Health Sciences Literature, Cochrane COVID-19 Study Register, WHO COVID-19 Database) identified studies published between January 2022 and March 2024<strong>.</strong> Studies included people with at least one of the following comorbidities: cardiovascular/cerebrovascular disease, chronic lung conditions, diabetes, and obesity. Studies were synthesized quantitatively using random-effect models. Evaluated outcomes were risk of death, hospitalization, intensive care unit (ICU) admission, and any combination of these outcomes.</div></div><div><h3>Results</h3><div>Of 72 studies, 68 were meta-analyzed. Participant numbers per comorbidity ranged from 328,870 to 13,720,480. Risks of death, hospitalization, and the combined outcome were increased in individuals with cerebrovascular disease, chronic obstructive pulmonary disease, diabetes, respiratory diseases, heart disease, and heart failure (pooled relative risk [RR] range: 1.27 [heart disease, hospitalization; 95% CI: 1.17-1.38] to 1.78 [heart failure, death: 95% CI: 1.46-2.16]). Diabetes and obesity were associated with increased ICU admission risk (RR: 1.20, 95% CI: 1.04-1.38; RR: 1.32, 95% CI: 1.11-1.57, respectively).</div></div><div><h3>Conclusion</h3><div>During the Omicron era, individuals with comorbidities faced increased risks of severe outcomes from COVID-19.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"158 ","pages":"Article 107958"},"PeriodicalIF":4.8000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1201971225001821","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

This is the first meta-analysis assessing mortality and hospitalization risk from COVID-19 in individuals with comorbidities versus those without during the Omicron era.

Methods

A systematic search (Embase, MEDLINE, PubMed, Europe PMC, Latin American and Caribbean Health Sciences Literature, Cochrane COVID-19 Study Register, WHO COVID-19 Database) identified studies published between January 2022 and March 2024. Studies included people with at least one of the following comorbidities: cardiovascular/cerebrovascular disease, chronic lung conditions, diabetes, and obesity. Studies were synthesized quantitatively using random-effect models. Evaluated outcomes were risk of death, hospitalization, intensive care unit (ICU) admission, and any combination of these outcomes.

Results

Of 72 studies, 68 were meta-analyzed. Participant numbers per comorbidity ranged from 328,870 to 13,720,480. Risks of death, hospitalization, and the combined outcome were increased in individuals with cerebrovascular disease, chronic obstructive pulmonary disease, diabetes, respiratory diseases, heart disease, and heart failure (pooled relative risk [RR] range: 1.27 [heart disease, hospitalization; 95% CI: 1.17-1.38] to 1.78 [heart failure, death: 95% CI: 1.46-2.16]). Diabetes and obesity were associated with increased ICU admission risk (RR: 1.20, 95% CI: 1.04-1.38; RR: 1.32, 95% CI: 1.11-1.57, respectively).

Conclusion

During the Omicron era, individuals with comorbidities faced increased risks of severe outcomes from COVID-19.

查看原文本刊更多论文

欧米克隆时代共病人群中COVID-19严重后果的风险：系统回顾和荟萃分析

背景：这是第一项评估在Omicron时代，有合并症的个体与无合并症的个体的COVID-19死亡率和住院风险的荟萃分析。方法：系统检索（Embase、MEDLINE、PubMed、Europe PMC、Latin American and Caribbean Health Sciences Literature、Cochrane COVID-19 Study Register、WHO COVID-19数据库），确定了2022年1月至2024年3月间发表的研究。研究包括至少有以下合并症之一的人：心脑血管疾病、慢性肺病、糖尿病和肥胖。研究采用随机效应模型进行定量综合。评估的结局是死亡风险、住院、重症监护病房（ICU）入院，以及这些结局的任何组合。结果：72项研究中，68项进行了meta分析。每个共病的参与者人数从328,870到13,720,480不等。脑血管疾病、慢性阻塞性肺病、糖尿病、呼吸系统疾病、心脏病和心力衰竭患者的死亡、住院和综合结局风险增加(合并相对危险度[RR]范围：1.27[心脏病、住院；95% CI: 1.17-1.38]至1.78[心力衰竭，死亡：95% CI: 1.46-2.16])。糖尿病和肥胖与ICU入院风险增加相关(RR: 1.20, 95% CI: 1.04-1.38；RR: 1.32, 95% CI: 1.11-1.57)。结论：在欧米克隆时代，患有合并症的个体面临COVID-19严重后果的风险增加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Infectious Diseases 医学-传染病学

CiteScore

18.90

自引率

2.40%

发文量

1020

审稿时长

30 days

期刊介绍： International Journal of Infectious Diseases (IJID) Publisher: International Society for Infectious Diseases Publication Frequency: Monthly Type: Peer-reviewed, Open Access Scope: Publishes original clinical and laboratory-based research. Reports clinical trials, reviews, and some case reports. Focuses on epidemiology, clinical diagnosis, treatment, and control of infectious diseases. Emphasizes diseases common in under-resourced countries.